Synergistic Antiproliferative Effects of a New Cucurbitacin B Derivative and Chemotherapy Drugs on Lung Cancer Cell Line A549

Mostrar otras versiones (1)

Nonsmall cell lung cancer (NSCLC) represents an important cause of mortality worldwide due to its aggressiveness and growing resistance to currently available therapy. Cucurbitacins have emerged as novel potential anticancer agents showing strong antiproliferative effects and can be promising candid...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Marostica, L.L
Otros Autores: Silva, I.T, Kratz, J.M, Persich, L., Geller, F.C, Lang, K.L, Caro, M.S.B, Durán, F.J, Schenkel, E.P, Simões, C.M.O
Formato: Capítulo de libro
Lenguaje:Inglés
Publicado: American Chemical Society 2015
Acceso en línea:Registro en Scopus
DOI
Handle
Registro en la Biblioteca Digital
Aporte de:Registro referencial: Solicitar el recurso aquí
Biblioteca Central Dr. Luis F. Leloir (FCEN) de Universidad de Buenos Aires
LEADER 20858caa a22020417a 4500
001 PAPER-24640
003 AR-BaUEN
005 20230518205632.0
008 190411s2015 xx ||||fo|||| 00| 0 eng|d
024 7 |2 scopus  |a 2-s2.0-84944754711 
024 7 |2 cas  |a acetylcysteine, 616-91-1; buthionine sulfoximine, 5072-26-4; caspase, 186322-81-6; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; F actin, 39409-31-9; irinotecan, 100286-90-6; paclitaxel, 33069-62-4; survivin, 195263-98-0; camptothecin, 7689-03-4; Actins; Antineoplastic Agents; BIRC5 protein, human; Camptothecin; Cisplatin; cucurbitacin B; Inhibitor of Apoptosis Proteins; irinotecan; Paclitaxel; Reactive Oxygen Species; TP53 protein, human; Triterpenes; Tumor Suppressor Protein p53 
040 |a Scopus  |b spa  |c AR-BaUEN  |d AR-BaUEN 
030 |a CRTOE 
100 1 |a Marostica, L.L. 
245 1 0 |a Synergistic Antiproliferative Effects of a New Cucurbitacin B Derivative and Chemotherapy Drugs on Lung Cancer Cell Line A549 
260 |b American Chemical Society  |c 2015 
270 1 0 |m Simões, C.M.O.; Laboratório de Virologia Aplicada, Departamento de Cieîncias Farmaceîuticas, CCS, Universidade Federal de Santa Catarina (UFSC), Campus Universitário TrindadeBrazil 
506 |2 openaire  |e Política editorial 
504 |a Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F., Wong, K.-K., Non-small cell lung cancers: a heterogeneous set of diseases (2014) Nat. Rev. Cancer, 14, pp. 535-546 
504 |a Siegel, R.L., Miller, K.D., Jemal, A., Cancer Statistics, 2015 (2015) Ca-Cancer J. Clin., 65, pp. 5-29 
504 |a Koh, P.K., Faivre-Finn, C., Blackhall, F.H., De Ruysscher, D., Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy (2012) Cancer Treat. Rev., 38, pp. 626-640 
504 |a Ríos, I., Andújar, J.M., Escandell, R.M., Recio, M.C., Cucurbitacins as inducers of cell death and a rich source of potential cancer compounds (2012) Curr. Pharm. Des., 18, pp. 1663-1676 
504 |a Chen, X., Bao, J., Guo, J., Ding, Q., Lu, J., Huang, M., Wang, Y., Biological activities and potential molecular targets of cucurbitacins: a focus on cancer (2012) Anti-Cancer Drugs, 23, pp. 777-787 
504 |a Silva, I.T., Carvalho, A., Lang, K.L., Dudek, S.E., Durán, F.J., Caro, M.S.B., Rapp, U.R., Ludwig, S., In vitro and in vivo antitumor activity of a novel semisynthetic derivative of cucurbitacin B (2015) PLoS One, 10, pp. 1-19 
504 |a Lang, K.L., Guimarães, T., Machado, V.R., Zimmermann, L., Silva, I.T., Teixeira, M.R., Durán, F.J., Schenkel, E.P., New cytotoxic cucurbutacins from Wilbrandia ebracteata Cogn (2011) Planta Med., 77, pp. 1648-1651 
504 |a Lang, K., Silva, I.T., Zimmermann, L., Machado, V.R., Teixeira, M.R., Lapuh, M.I., Galleti, M.A., Durán, F.J., Synthesis and cytotoxic activity evaluation of dihydrocucurbitacin B and cucurbitacin B derivatives (2012) Bioorg. Med. Chem., 20, pp. 3016-3030 
504 |a Lang, K.L., Silva, I.T., Machado, V.R., Zimmermann, L., Caro, M.S.B., Simões, C.M.O., Schenkel, E.P., Melo, E.B., Multivariate SAR and QSAR of cucurbitacin derivatives as cytotoxic compounds in a human lung adenocarcinoma cell line (2014) J. Mol. Graphics Modell., 48, pp. 70-79 
504 |a Silva, I.T., Teixeira, M.R., Lang, K., Guimarães, T.R., Dudek, S.E., Durán, F.J., Ludwig, S., Simões, C.M.O., Proliferative inhibition and apoptotic mechanism on human non-small-cell lung cancer (A549 cells) of a novel cucurbitacin from Wilbrandia ebracteata Cogn (2013) Int. J. Cancer Res., 9, pp. 54-68 
504 |a Thoennissen, N.H., Iwanski, G.B., Doan, N.B., Okamoto, R., Lin, P., Abbassi, S., Song, J.H., Koeffler, P., Cucurbitacin B Induces Apoptosis by Inhibition of the JAK/STAT Pathway and Potentiates Antiproliferative Effects of Gemcitabine on Pancreatic Cancer Cells (2009) Cancer Res., 69, pp. 5876-5884 
504 |a Liu, T., Peng, H., Zhang, M., Deng, Y., Wu, Z., Cucurbitacin B, a small molecule inhibitor of the Stat3 signaling pathway, enhances the chemosensitivity of laryngeal squamous cell carcinoma cells to cisplatin (2010) Eur. J. Pharmacol., 641, pp. 15-22 
504 |a Chen, W., Leiter, A., Yin, D., Meiring, M., Louw, V., Koeffler, H.P., Cucurbitacin B inhibits growth, arrest the cell cycle, and potentiates antiproliferative efficacy of cisplatin in cutaneous squamous cell carcinoma cell lines (2010) Int. J. Oncol., 37, pp. 737-743 
504 |a Iwanski, G.B., Lee, D., En-Gal, S., Doan, N.B., Castor, B., Vogt, M., Toh, M., Koeffler, P., Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer (2010) Br. J. Pharmacol., 160, pp. 998-1007 
504 |a Martinelli, E., Troiani, T., Morgillo, F., Rodolico, G., Vitagliano, D., Pia Morelli, M., Tuccillo, C., Ciardiello, F., Synergistic antitumor activity of Sorafenib in combination with Epidermal Growth Factor Receptor inhibitors in colorectal and lung cancer cells (2010) Clin. Cancer Res., 16, pp. 4990-5001 
504 |a Li, C.J., Chu, C., Huang, L., Wang, M., Sheu, L., Yeh, J., Hsu, H., Synergistic anticancer activity of triptolide combined with cisplatin enhances apoptosis in gastric cancer in vitro and in vivo (2012) Cancer Lett., 319, pp. 203-213 
504 |a Hatakeyama, Y., Kobayashi, K., Nagano, T., Tamura, D., Yamamoto, M., Tachihara, M., Kotani, Y., Nishimura, Y., Synergistic effects of pemetrexed and amrubicin in non-small cell lung cancer cell lines (2014) Cancer Lett., 343, pp. 74-79 
504 |a Duangmano, S., Sae-Lim, P., Suksamrarn, A., Patmasiriwat, P., Domman, F.E., Cucurbitacin B causes increased radiation sensitivity of human breast cancer cells via G2/M cell cycle arrest (2012) J. Oncol., 2012, pp. 1-8 
504 |a Chang, C.-J., Chiang, C.-H., Song, W.-S., Tsai, S.-K., Woung, L.-C., Chang, C.-H., Jeng, S.-Y., Lu, K.-H., Inhibition of phosphorylated STAT3 by cucurbitacin I enhances chemoradiosensitivity in medulloblastoma-derived cancer stem cells (2012) Childs Nerv. Syst., 28, pp. 363-373 
504 |a Aribi, A., Gery, S., Lee, D.H., Thoennissen, N.H., Thoennissen, G.B., Alvarez, R., Ho, Q., Koeffler, H.P., The triterpenoid cucurbitacin B augments the antiproliferative activity of chemotherapy in human breast cancer (2013) Int. J. Cancer, 132, pp. 2730-2737 
504 |a Qu, Y., Wu, X., Yin, Y., Yang, Y., Ma, D., Li, H., Antitumor activity of selective MEK 1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models (2014) J. Exp. Clin. Cancer Res., 33, p. 52 
504 |a Vichai, V., Kirtikara, K., Sulforhodamine B colorimetric assay for cytotoxicity screening (2006) Nat. Protoc., 1, pp. 1112-1116 
504 |a Larsson, J., Gottfries, J., Muresan, S., Backlund, A., ChemGPS-NP: Tuned for navigation in biologically relevant chemical space (2007) J. Nat. Prod., 70, pp. 789-794 
504 |a Felth, J., Rickardson, L., Rosén, J., Wickstrom, M., Fryknas, M., Lindskog, M., Bohlin, L., Gullbo, J., Cytotoxic Effects of Cardiac Glycosides in Colon Cancer Cells, Alone and in Combination with Standard Chemotherapeutic Drugs (2009) J. Nat. Prod., 72, pp. 1969-1974 
504 |a Chou, T.C., Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies (2006) Pharmacol. Rev., 58 (3), pp. 621-681 
504 |a Franken, N.A.P., Rodermond, H.M., Stap, J., Haveman, J., Van Bree, C., Clonogenic assay of cells in vitro (2006) Nat. Protoc., 1, pp. 2315-2319 
504 |a Riccardi, C., Nicoletti, I., Analysis of apoptosis by propidium iodide staining and flow cytometry (2006) Nat. Protoc., 1, pp. 1458-1461 
504 |a Selinummi, J., Seppala, J., Yli-Harja, O., Puhakka, J.A., Software for quantification of labeled bacteria from digital microscope images by automated image analysis (2005) BioTechniques, 39, pp. 859-862 
504 |a Custodio, A., Méndez, M., Provencio, M., Targeted therapies for advanced non-small-cell lung cancer: current status and future implications (2012) Cancer Treat. Rev., 38, pp. 36-53 
504 |a Rosén, J., Lövgren, A., Kogej, T., Muresan, S., Gottfries, J., Backlund, A., ChemGPS NPWeb: chemical space navigation online (2009) J. Comput.-Aided Mol. Des., 23, pp. 253-259 
504 |a Rosén, J., Rickardson, L., Backlund, A., Gullbo, J., Bohlin, L., Larsson, R., Gottfries, J., ChemGPS-NP mapping of chemical compounds for prediction of anticancer mode of action (2009) QSAR Comb. Sci., 28, pp. 436-446 
504 |a Lee, C., Lin, Y., Chang, F., Chen, G., Backlund, A., Yang, J., Chen, Y., Wu, Y., Synthesis and biological evaluation of phenanthrenes as cytotoxic agents with pharmacophore modeling and ChemGPS-NP prediction as topo II inhibitors (2012) PLoS One, 7, pp. 1-14 
504 |a Kausar, H., Munagala, R., Bansal, S.S., Aqil, F., Vadhanan, M.V., Gupta, R.C., Cucurbitacin B potently suppresses non-small-cell lung cancer growth: Identification of intracellular thiols as critical targets (2013) Cancer Lett., 332, pp. 35-45 
504 |a Guo, J., Wu, G., Bao, J., Hao, W., Lu, J., Chen, X., Cucurbitacin B Induced ATM-Mediated DNA Damage Causes G2/M Cell Cycle Arrest in a ROS-Dependent Manner (2014) PLoS One, 9, pp. 1-12 
504 |a Andriani, F., Perego, P., Roz, L., Increased sensitivity to cisplatin in non-small cell lung cancer cell lines after FHIT gene transfer (2006) Neoplasia, 8, pp. 9-17 
504 |a Kaufmann, S.H., Peereboom, D., Buckwalter, C.A., Swingen, P.A., Grochow, L.B., Donehower, R.C., Rowinsky, E.K., Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines (1996) J. Natl. Cancer Inst., 88, pp. 734-741 
504 |a Odonkor, C.A., Achilefu, S., Differential activity of caspase-3 regulates susceptibility of lung and breast tumor cell lines to paclitaxel (2008) Open Biochem. J., 2, pp. 121-128 
504 |a Zhu, J.S., Ouyang, D.Y., Shi, Z.J., Xu, L.H., Zhang, Y.T., He, X.H., Cucurbitacin B Induces Cell Cycle Arrest, Apoptosis and Autophagy Associated with G Actin Reduction and Persistent Activation of Cofilin in Jurkat Cells (2012) Pharmacology, 89, pp. 348-356 
504 |a Duangmano, S., Sae-Lim, P., Suksamrarn, A., Patmasiriwat, P., Domman, F.E., Cucurbitacin B causes increased radiation sensitivity of human breast cancer cells via G2/M cell cycle arrest (2012) J. Oncol., 2012, pp. 1-8 
504 |a Yasuda, S., Yogosawa, S., Izutani, Y., Nakamura, Y., Watanabe, H., Sakai, T., Cucurbitacin B induces G2 arrest and apoptosis via a reactive oxygen species-dependent mechanism in human colon adenocarcinoma SW480 cells (2010) Mol. Nutr. Food Res., 54, pp. 559-565 
504 |a Huang, W., Yang, J., Lin, M., Chen, P., Chiou, S., Chueh, F., Lan, Y., Chung, J., Cucurbitacin E Induces G2/M Phase Arrest through STAT3/p53/p21 Signaling and Provokes Apoptosis via Fas/CD95 and Mitochondria-Dependent Pathways in Human Bladder Cancer T24 Cells (2012) Evid-Based Compl. Alt., 2012, pp. 1-11 
504 |a Zhu, J.S., Ouyang, D.Y., Shi, Z.J., Xu, L.H., Zhang, Y.T., He, X.H., Cucurbitacin B Induces Cell Cycle Arrest, Apoptosis and Autophagy Associated with G Actin Reduction and Persistent Activation of Cofilin in Jurkat Cells (2012) Pharmacology, 89, pp. 348-356 
504 |a Haritunians, T., Gueller, S., Zhang, L., Badr, R., Yin, D., Xing, H., Fung, M.C., Koeffler, P., Cucurbitacin B induces differentiation, cell cycle arrest, and actin cytoskeletal alterations in myeloid leukemia cells (2008) Leuk. Res., 32, pp. 1366-1373 
504 |a Knecht, D.A., LaFleur, R.A., Kahsai, A.W., Argueta, C.E., Beshir, A.B., Fenteany, G., Cucurbitacin I Inhibits Cell Motility by Indirectly Interfering with Actin Dynamics (2010) PLoS One, 5, pp. 1-11 
504 |a Zhang, T., Li, Y., Park, K.A., Byun, H.S., Won, M., Jeon, J., Lee, Y., Hur, G.M., Cucurbitacin induces autophagy through mitochondrial ROS production which counteracts to limit caspase-dependent apoptosis (2012) Autophagy, 8, pp. 559-576 
504 |a Park, S., Kim, J., Chi, G., Kim, G., Chang, Y., Moon, S., Nam, S., Choi, Y., Induction of apoptosis and autophagy by sodium selenite in A549 human lung carcinoma cells through generation of reactive oxygen species (2012) Toxicol. Lett., 212, pp. 252-261 
504 |a Gabrielsen, M., Schuldt, M., Munro, J., Borucka, D., Cameron, J., Baugh, M., Mleczak, A., Olson, M., Cucurbitacin covalent bonding to cysteine thiols: the filamentous-actin severing protein Cofilin1 as an exemplary target (2013) Cell Commun. Signaling, 11, p. 58 
504 |a Blaschuk, O.W., Devemy, E., Cadherins as novel targets for anticancer therapy (2009) Eur. J. Pharmacol., 625, pp. 195-198 
504 |a Shanmugam, M.K., Nguyen, A.H., Kumar, A.P., Tan, B.K.H., Sethi, G., Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: Potential role in prevention and therapy of cancer (2012) Cancer Lett., 320, pp. 158-170 
504 |a Zhang, T., Li, J., Dong, Y., Zhai, D., Lai, L., Dai, F., Deng, H., Yi, M., Cucurbitacin E inhibits breast tumor metastasis by suppressing cell migration and invasion (2012) Breast Cancer Res. Treat., 135, pp. 445-458 
504 |a Deryugina, E.I., Quigley, J.P., Matrix Metalloproteinases and tumor metastasis (2006) Cancer Metastasis Rev., 25, pp. 9-34 
504 |a Muller, C.B., Barros, R.L.S., Castro, M.A.A., Lopes, F.M., Meurer, R.T., Roehe, A., Mazzini, G., Klamt, F., Validation of cofilin-1 as a biomarker in non-small cell lung cancer: application of quantitative method in a retrospective cohort (2011) J. Cancer Res. Clin. Oncol., 137, pp. 1309-1316 
504 |a Nakashima, S., Matsuda, H., Kurume, A., Oda, Y., Nakamura, S., Yamashita, M., Yoshikawa, M., Cucurbitacin E as a new inhibitor of cofilin phosphorylation in human leukemia U937 cells (2010) Bioorg. Med. Chem. Lett., 20, pp. 2994-2997 
504 |a Zhang, Y.-T., Ouyang, D.-Y., Xu, L.-H., Zha, Q.-B., He, X.-H., Formation of Cofilin-Actin rods following cucurbitacin-B-induced aggregation depends on slingshot Homolog1-Mediated Cofilin Hyperactivation (2013) J. Cell. Biochem., 114, pp. 2415-2429 
504 |a Siveen, K.S., Sikka, S., Surana, R., Dai, X., Zhang, J., Kumar, A.P., Tan, B.K.H., Bishayee, A., Targeting the Stat3 signaling pathway in cancer: Role of synthetic and natural inhibitors (2014) Biochim. Biophys. Acta, Rev. Cancer, 1845, pp. 136-154 
520 3 |a Nonsmall cell lung cancer (NSCLC) represents an important cause of mortality worldwide due to its aggressiveness and growing resistance to currently available therapy. Cucurbitacins have emerged as novel potential anticancer agents showing strong antiproliferative effects and can be promising candidates for combined treatments with clinically used anticancer agents. This study investigates the synergistic antiproliferative effects of a new semisynthetic derivative of cucurbitacin B (DACE) with three chemotherapy drugs: cisplatin (CIS), irinotecan (IRI), and paclitaxel (PAC) on A549 cells. The most effective combinations were selected for studies of the mechanism of action. Using an in silico tool, DACE seems to act by a different mechanism of action when compared with that of different classes of drugs already used in clinical settings. DACE also showed potent synergic effects with drugs, and the most potent combinations induced G2/M cell cycle arrest by modulating survivin and p53 expression, disruption of F-actin cytoskeleton, and cell death by apoptosis. These treatments completely inhibited the clonogenic potential and did not reduce the proliferation of nontumoral lung cells (MRC-5). DACE also showed relevant antimigratory and anti-invasive effects, and combined treatments modulated cell migration signaling pathways evolved with metastasis progression. The effects of DACE associated with drugs was potentiated by the oxidant agent l-buthionine-sulfoximine (BSO), and attenuated by N-acetilcysteine (NAC), an antioxidant agent. The antiproliferative effects induced by combined treatments were attenuated by a pan-caspase inhibitor, indicating that the effects of these treatments are dependent on caspase activity. Our data highlight the therapeutic potential of DACE used in combination with known chemotherapy drugs and offer important insights for the development of more effective and selective therapies against lung cancer. © 2015 American Chemical Society.  |l eng 
536 |a Detalles de la financiación: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, CAPES 
536 |a Detalles de la financiación: Conselho Nacional de Desenvolvimento Científico e Tecnológico, CNPq, 2671/2012-9 
593 |a Departamento de Cieîncias Farmaceîuticas, Universidade Federal de Santa Catarina, Campus Trindade, Florianópolis, Santa Catarina CEP 88040-900, Brazil 
593 |a Departamento de Química, Universidade Federal de Santa Catarina, Campus Trindade, Florianópolis, Santa Catarina CEP 88040-900, Brazil 
593 |a UMYMFOR-CONICET, Departamento de Química Orgánica, Universidad de Buenos AiresBuenos Aires, Argentina 
690 1 0 |a 2 DEOXY 2 AMINE CUCURBITACIN E 
690 1 0 |a ACETYLCYSTEINE 
690 1 0 |a BUTHIONINE SULFOXIMINE 
690 1 0 |a CASPASE 
690 1 0 |a CISPLATIN 
690 1 0 |a CUCURBITACIN 
690 1 0 |a F ACTIN 
690 1 0 |a IRINOTECAN 
690 1 0 |a PACLITAXEL 
690 1 0 |a PROTEIN P53 
690 1 0 |a REACTIVE OXYGEN METABOLITE 
690 1 0 |a SURVIVIN 
690 1 0 |a UNCLASSIFIED DRUG 
690 1 0 |a ACTIN 
690 1 0 |a ANTINEOPLASTIC AGENT 
690 1 0 |a BIRC5 PROTEIN, HUMAN 
690 1 0 |a CAMPTOTHECIN 
690 1 0 |a CISPLATIN 
690 1 0 |a CUCURBITACIN B 
690 1 0 |a INHIBITOR OF APOPTOSIS PROTEIN 
690 1 0 |a IRINOTECAN 
690 1 0 |a PACLITAXEL 
690 1 0 |a PROTEIN P53 
690 1 0 |a REACTIVE OXYGEN METABOLITE 
690 1 0 |a TP53 PROTEIN, HUMAN 
690 1 0 |a TRITERPENE 
690 1 0 |a A549 CELL LINE 
690 1 0 |a ANTIPROLIFERATIVE ACTIVITY 
690 1 0 |a APOPTOSIS 
690 1 0 |a ARTICLE 
690 1 0 |a CANCER INHIBITION 
690 1 0 |a CELL PROLIFERATION 
690 1 0 |a COMPARATIVE EFFECTIVENESS 
690 1 0 |a COMPUTER MODEL 
690 1 0 |a CONTROLLED STUDY 
690 1 0 |a CYTOSKELETON 
690 1 0 |a DRUG MECHANISM 
690 1 0 |a DRUG POTENCY 
690 1 0 |a DRUG POTENTIATION 
690 1 0 |a DRUG STRUCTURE 
690 1 0 |a ENZYME ACTIVITY 
690 1 0 |a ENZYME INHIBITION 
690 1 0 |a FLOW CYTOMETRY 
690 1 0 |a G2 PHASE CELL CYCLE CHECKPOINT 
690 1 0 |a HUMAN 
690 1 0 |a HUMAN CELL 
690 1 0 |a IC50 
690 1 0 |a METASTASIS INHIBITION 
690 1 0 |a MIGRATION INHIBITION 
690 1 0 |a PROTEIN EXPRESSION 
690 1 0 |a ANALOGS AND DERIVATIVES 
690 1 0 |a CELL MOTION 
690 1 0 |a CHEMISTRY 
690 1 0 |a DRUG EFFECTS 
690 1 0 |a LUNG NEOPLASMS 
690 1 0 |a M PHASE CELL CYCLE CHECKPOINT 
690 1 0 |a METABOLISM 
690 1 0 |a PATHOLOGY 
690 1 0 |a TUMOR CELL LINE 
690 1 0 |a ACTINS 
690 1 0 |a ANTINEOPLASTIC AGENTS 
690 1 0 |a APOPTOSIS 
690 1 0 |a CAMPTOTHECIN 
690 1 0 |a CELL LINE, TUMOR 
690 1 0 |a CELL MOVEMENT 
690 1 0 |a CELL PROLIFERATION 
690 1 0 |a CISPLATIN 
690 1 0 |a DRUG SYNERGISM 
690 1 0 |a G2 PHASE CELL CYCLE CHECKPOINTS 
690 1 0 |a HUMANS 
690 1 0 |a INHIBITOR OF APOPTOSIS PROTEINS 
690 1 0 |a LUNG NEOPLASMS 
690 1 0 |a M PHASE CELL CYCLE CHECKPOINTS 
690 1 0 |a PACLITAXEL 
690 1 0 |a REACTIVE OXYGEN SPECIES 
690 1 0 |a TRITERPENES 
690 1 0 |a TUMOR SUPPRESSOR PROTEIN P53 
700 1 |a Silva, I.T. 
700 1 |a Kratz, J.M. 
700 1 |a Persich, L. 
700 1 |a Geller, F.C. 
700 1 |a Lang, K.L. 
700 1 |a Caro, M.S.B. 
700 1 |a Durán, F.J. 
700 1 |a Schenkel, E.P. 
700 1 |a Simões, C.M.O. 
773 0 |d American Chemical Society, 2015  |g v. 28  |h pp. 1949-1960  |k n. 10  |p Chem. Res. Toxicol.  |x 0893228X  |w (AR-BaUEN)CENRE-1767  |t Chemical Research in Toxicology 
856 4 1 |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-84944754711&doi=10.1021%2facs.chemrestox.5b00153&partnerID=40&md5=f33bd5277cce54391556e1f6a8f4c5f0  |y Registro en Scopus 
856 4 0 |u https://doi.org/10.1021/acs.chemrestox.5b00153  |y DOI 
856 4 0 |u https://hdl.handle.net/20.500.12110/paper_0893228X_v28_n10_p1949_Marostica  |y Handle 
856 4 0 |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_0893228X_v28_n10_p1949_Marostica  |y Registro en la Biblioteca Digital 
961 |a paper_0893228X_v28_n10_p1949_Marostica  |b paper  |c PE 
962 |a info:eu-repo/semantics/article  |a info:ar-repo/semantics/artículo  |b info:eu-repo/semantics/publishedVersion 
999 |c 85593 

Ejemplares similares